BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30114962)

  • 21. Targeting kallikrein-related peptidases in prostate cancer.
    Mavridis K; Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2014 Apr; 18(4):365-83. PubMed ID: 24571737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.
    Stefanini AC; da Cunha BR; Henrique T; Tajara EH
    Dis Markers; 2015; 2015():946572. PubMed ID: 26783378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.
    Yoon H; Blaber SI; Evans DM; Trim J; Juliano MA; Scarisbrick IA; Blaber M
    Protein Sci; 2008 Nov; 17(11):1998-2007. PubMed ID: 18697857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid.
    Oikonomopoulou K; Batruch I; Smith CR; Soosaipillai A; Diamandis EP; Hollenberg MD
    Biol Chem; 2010 Apr; 391(4):381-90. PubMed ID: 20180649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kallikreins as microRNA targets: an in silico and experimental-based analysis.
    Chow TF; Crow M; Earle T; El-Said H; Diamandis EP; Yousef GM
    Biol Chem; 2008 Jun; 389(6):731-8. PubMed ID: 18627289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer.
    Di Meo A; Wang C; Cheng Y; Diamandis EP; Yousef GM
    Biol Chem; 2018 Sep; 399(9):973-982. PubMed ID: 29604203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parallel overexpression of seven kallikrein genes in ovarian cancer.
    Yousef GM; Polymeris ME; Yacoub GM; Scorilas A; Soosaipillai A; Popalis C; Fracchioli S; Katsaros D; Diamandis EP
    Cancer Res; 2003 May; 63(9):2223-7. PubMed ID: 12727843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
    Yoon H; Laxmikanthan G; Lee J; Blaber SI; Rodriguez A; Kogot JM; Scarisbrick IA; Blaber M
    J Biol Chem; 2007 Nov; 282(44):31852-64. PubMed ID: 17823117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural characterization and expression of five novel canine kallikrein-related peptidases in mammary cancer.
    Angelopoulou K; Karagiannis GS
    Mamm Genome; 2010 Oct; 21(9-10):516-24. PubMed ID: 20853168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer.
    Kim H; Scorilas A; Katsaros D; Yousef GM; Massobrio M; Fracchioli S; Piccinno R; Gordini G; Diamandis EP
    Br J Cancer; 2001 Mar; 84(5):643-50. PubMed ID: 11237385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
    Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U
    Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.
    Shahinian H; Loessner D; Biniossek ML; Kizhakkedathu JN; Clements JA; Magdolen V; Schilling O
    Mol Oncol; 2014 Feb; 8(1):68-82. PubMed ID: 24120346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications.
    Gabril M; White NM; Moussa M; Chow TF; Metias SM; Fatoohi E; Yousef GM
    Biol Chem; 2010 Apr; 391(4):403-9. PubMed ID: 20128686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
    Figueroa CD; Molina L; Bhoola KD; Ehrenfeld P
    Biol Chem; 2018 Sep; 399(9):937-957. PubMed ID: 29885274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
    Avgeris M; Mavridis K; Scorilas A
    Biol Chem; 2012 Apr; 393(5):301-17. PubMed ID: 22505514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.
    Debela M; Beaufort N; Magdolen V; Schechter NM; Craik CS; Schmitt M; Bode W; Goettig P
    Biol Chem; 2008 Jun; 389(6):623-32. PubMed ID: 18627343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional roles of human kallikrein-related peptidases.
    Sotiropoulou G; Pampalakis G; Diamandis EP
    J Biol Chem; 2009 Nov; 284(48):32989-94. PubMed ID: 19819870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.
    Pasic MD; Olkhov E; Bapat B; Yousef GM
    Biol Chem; 2012 Apr; 393(5):319-30. PubMed ID: 22505515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
    de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
    J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.
    Emami N; Diamandis EP
    Clin Chem; 2008 Oct; 54(10):1600-7. PubMed ID: 18687738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.